Sequoia Financial Advisors LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Sequoia Financial Advisors LLC increased its stake in Alnylam Pharmaceuticals by 15.4%, owning 3,917 shares worth approximately $1.28 million after purchasing an additional 522 shares.
• Insider selling was notable, with executives Pushkal Garg and Tolga Tanguler selling shares totaling over $2 million, reflecting decreases in their ownership by 13% and 4.87%, respectively.
• Several analysts have upgraded their price targets for Alnylam Pharmaceuticals, with a consensus rating of "Moderate Buy" and an average target price of $457.08.

Sequoia Financial Advisors LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,917 shares of the biopharmaceutical company's stock after purchasing an additional 522 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $1,277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its stake in shares of Alnylam Pharmaceuticals by 15.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 312,216 shares of the biopharmaceutical company's stock worth $100,552,000 after purchasing an additional 41,292 shares during the last quarter. OFI Invest Asset Management raised its stake in shares of Alnylam Pharmaceuticals by 26.2% in the second quarter. OFI Invest Asset Management now owns 381 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 79 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 47.3% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,390 shares of the biopharmaceutical company's stock worth $4,368,000 after purchasing an additional 4,302 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $2,120,000. Finally, Aberdeen Group plc grew its holdings in shares of Alnylam Pharmaceuticals by 1.5% in the second quarter. Aberdeen Group plc now owns 218,624 shares of the biopharmaceutical company's stock worth $70,364,000 after acquiring an additional 3,239 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insiders Place Their Bets

In other news, EVP Pushkal Garg sold 3,022 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,129,377.08. This trade represents a 13.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Tolga Tanguler sold 1,405 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the sale, the executive vice president directly owned 27,438 shares of the company's stock, valued at $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $481.07 on Friday. The stock has a 50 day moving average of $455.04 and a 200 day moving average of $350.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $488.39. The firm has a market cap of $63.06 billion, a PE ratio of -194.77 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The firm's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ALNY shares. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Jefferies Financial Group lifted their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Truist Financial started coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $385.00 price objective for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Twenty-four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $457.08.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.